ThesisTimes
TimesDiscover
Log inSign up free
Sign up

Features

All featuresPlatform capabilities in one catalog.
  • Copilot
  • Portfolio Analytics
  • Research
  • Inbox
  • Dashboards
  • Charting
  • Options

For investors

Browse by investor typeSee Thesis framed for how you manage money.
  • Concentrated portfolios
  • Covered call investors
  • Busy professionals
  • Stock research
  • Swing traders
  • Options beginners
TimesDiscover
Log inSign up free

Market analysis for active investors

Thesis Times

Saturday, June 6, 2026·2 stories

AllAMGNDJIGOOGLLLYABTABVXALBAPOARESASHRBABX

Front page

Biotech & Clinical Trials·Feb 5

Hims & Hers Undercuts Wegovy With a Cheaper Pill - and Novo Nordisk Drops 8%

The telehealth disruptor's compounded semaglutide offering is reigniting the brand-name vs. compounded drug battle, putting pressure on NVO and LLY at a critical moment for the obesity drug market.

HIMS · NVO · LLY · NONOF

Biotech & Clinical Trials·Feb 5

CVS Drops Prolia and Forteo From Formularies, Putting Amgen and Lilly Revenue at Risk

Biotech & Clinical Trials·Feb 5

CVS Drops Prolia and Forteo From Formularies, Putting Amgen and Lilly Revenue at Risk

Biotech & Clinical Trials·Feb 5

Hims & Hers Undercuts Wegovy With a Cheaper Pill - and Novo Nordisk Drops 8%

The telehealth disruptor's compounded semaglutide offering is reigniting the brand-name vs. compounded drug battle, putting pressure on NVO and LLY at a critical moment for the obesity drug market.

HIMS · NVO · LLY · NONOF

Features·Discover·Terms·Privacy